About US
Contact us
-
Gilead sees a blockbuster 2021 for COVID-19 drug Veklury but can grow without it: CFOEarly in the COVID-19 pandemic, as researchers scrambled to find medicines that could treat the new and mysterious disease, Gilead Sciences' remdesivir quickly marched to worldwide prominence based o2021/2/7
-
No need 'to start at square one': FDA plans to lay out a speedy path for COVID-19 vaccines, drugs against variantsNew coronavirus variants have prompted COVID-19 vaccine makers to start developing updates to their existing offerings. To speed their journey to a pandemic-fatigued public, the FDA says it’s develop2021/2/7
-
Could combining Pfizer's and AZ's COVID-19 vaccines fill supply gaps? U.K. researchers aim to find outGiven that the COVID-19 vaccines from Pfizer and AstraZeneca each require one dose, followed a few weeks later by a booster shot, could the two products be used interchangeably? That’s the question r2021/2/5
-
Novo Nordisk plots $1.3B in spending as it expands API production—and advances new oral medsNovo Nordisk is off and running with its launch for oral semaglutide, a Type 2 diabetes med carrying blockbuster expectations. But the company also sees potential new uses for its oral delivery platf2021/2/5
-
Pfizer's new rare-disease meds Vyndaqel, Vyndamax reach blockbuster threshold despite pandemic hurdlesWhile the COVID-19 pandemic dominated headlines at Pfizer and beyond last year, behind the scenes, the company has been busy with its launch of rare heart diseasemedsVyndaqelandVyndamax. And those ef2021/2/3
-
Vertex CEO faces growing pressure for pipeline deals despite major hike in Trikafta salesDuring last month’s J.P. Morgan healthcare conference, Vertex CEO Reshma Kewalramani, M.D., said the company is actively scouting for “tools and technology” to acquire, specifically mid- and late-sta2021/2/3
-
Fierce Pharma Asia—Lilly's COVID-19 antibody results, Asahi Kasei deal; Takeda's EGFR lung cancer dataEli Lilly said its two-drug COVID-19 antibody cocktail could prevent hospitalization or death among high-risk patients. The Indianapolis pharma in-licensed a neuroinflammatory pain candidate from Asa2021/2/1
-
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020A manufacturing shortfall likely cost Bristol Myers Squibb the chance of an FDA approval for CAR-T therapy liso-cel by the end of 2020—and sent a potential $9-apiece Celgene deal sweetener into the t2021/2/1
-
Pfizer's Xeljanz fails RA safety study, making a tough rivalry with AbbVie's Rinvoq even tougherPfizer has had a tough couple of years marketing its rheumatoid arthritis drug Xeljanz, as regulatory agencies have slapped warnings on the JAK inhibitor about potential cardiovascular side effects a2021/1/29
-
MIT spinout Continuus Pharmaceuticals nets $69M to onshore production of critical medsMassachusetts Institute of Technology (MIT) spinout Continuus Pharmaceuticals is joining the push to bring drug manufacturing stateside, and it's tappedsome cutting-edge tech for the job. Armed with2021/1/29